CLEFMA
Based on 1 Customer Validation
CLEFMA is a curcuminoid with antitumor activity. CLEFMA inhibits tumor growth is associated with NF-κB-regulated anti-inflammatory and anti-metastatic effects.
For research use only. We do not sell to patients.
- Purity : 98.03%
- CAS No.: 1246964-32-8
- Formula: C23H17Cl2NO4
- Molecular Weight:442.29
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NCI-H441 | IC50 |
1 μM
Compound: 29, CLEFMA
|
Antiproliferative activity against human H441 cells assessed as decrease of hexosaminidase activity after 24 hrs
Antiproliferative activity against human H441 cells assessed as decrease of hexosaminidase activity after 24 hrs
|
[PMID: 20638855] |
In Vitro
CLEFMA (1-100 μM; 24-72 h) has anti-proliferative activity[1].
CLEFMA inhibits the viability of H441 and A549 cells, with IC50s of 6.4 and 8.9 μM, respectively[2].
CLEFMA (5-10 μM; 24 h) induces apoptosis in H441 and A549 cells[2].
CLEFMA (1 and 10 μM; 24 h) induces autophagic death in H441 cells[1].
CLEFMA (1-20 μM) reduces the DNA-binding activity of NF-κB in H441 cells in a dose-dependent manner[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:PANC-1, MiaPaCa-2, PC-3 and H441 cells
-
Concentration:1, 10, 25, 100 μM
-
Incubation Time:24, 48, 72 h
-
Result:Inhibits cells proliferation in a dose-dependent manner.
In Vivo
CLEFMA (0.2-0.4 mg/kg; i.p. daily for 4 weeks) down-regulates the expression of anti-apoptotic markers cIAP1, Bcl-xL, Bcl-2 and survivin, and induces the cleavage of pro-apoptotic protein BID and the expression of pro-apoptotic BAX in tumor tissue[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male athymic nu/nu mice (4 weeks old) are injected H441 cells[2]
-
Dosage:0.2, 0.4 mg/kg
-
Administration:I.p. daily for 4 weeks
-
Result:Inhibited tumor growth up to 96% tumor at dose of 0.4 mg/kg.
Chemical Information
-
CAS No. 1246964-32-8
-
Appearance Solid
-
Molecular Weight 442.29
-
Formula C23H17Cl2NO4
-
Color Light yellow to yellow
-
SMILES
O=C(O)/C=C\C(N1C/C(C(/C(C1)=C/C2=CC=CC=C2Cl)=O)=C\C3=CC=CC=C3Cl)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 116.67 mg/mL (263.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (536 KB)
- English - EN (536 KB)
- Français - FR (536 KB)
- Deutsch - DE (536 KB)
- Norwegian - NO (536 KB)
- Español - ES (536 KB)
- Swedish - SV (536 KB)
- Italian - IT (536 KB)
- Korean - KR (536 KB)
- Portuguese - PT (536 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lagisetty P, et, al. CLEFMA-an anti-proliferative curcuminoid from structure-activity relationship studies on 3,5-bis(benzylidene)-4-piperidones. Bioorg Med Chem. 2010 Aug 15; 18(16):6109-20. [Content Brief]
[2]. Yadav VR, et, al. Preclinical evaluation of 4-[3,5-bis(2-chlorobenzylidene)-4-oxo-piperidine-1-yl]-4-oxo-2-butenoic acid, in a mouse model of lung cancer xenograft. Br J Pharmacol. 2013 Dec; 170(7): 1436-48. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2610 mL | 11.3048 mL | 22.6096 mL | 56.5240 mL |
| 5 mM | 0.4522 mL | 2.2610 mL | 4.5219 mL | 11.3048 mL | |
| 10 mM | 0.2261 mL | 1.1305 mL | 2.2610 mL | 5.6524 mL | |
| 15 mM | 0.1507 mL | 0.7537 mL | 1.5073 mL | 3.7683 mL | |
| 20 mM | 0.1130 mL | 0.5652 mL | 1.1305 mL | 2.8262 mL | |
| 25 mM | 0.0904 mL | 0.4522 mL | 0.9044 mL | 2.2610 mL | |
| 30 mM | 0.0754 mL | 0.3768 mL | 0.7537 mL | 1.8841 mL | |
| 40 mM | 0.0565 mL | 0.2826 mL | 0.5652 mL | 1.4131 mL | |
| 50 mM | 0.0452 mL | 0.2261 mL | 0.4522 mL | 1.1305 mL | |
| 60 mM | 0.0377 mL | 0.1884 mL | 0.3768 mL | 0.9421 mL | |
| 80 mM | 0.0283 mL | 0.1413 mL | 0.2826 mL | 0.7065 mL | |
| 100 mM | 0.0226 mL | 0.1130 mL | 0.2261 mL | 0.5652 mL |